Biovica International
Biovica International is a Swedish life science company focused on blood-based biomarker assays for monitoring cancer treatment response. Its core product, DiviTum TKa, is used in clinical settings and in pharmaceutical development programs, with operations centered in Sweden and the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDiviTum TKa testing used by clinicians to monitor cancer treatment response.
Biomarker testing, study support, and consulting for pharma and biotech trials.
Customers
Biovica sells primarily to healthcare providers and clinical users in the U.S. who use DiviTum TKa to monitor breast cancer treatment response. It also serves pharmaceutical and biotechnology companies that use the platform in clinical studies, biomarker programs, and companion diagnostic development. Academic institutions and CROs can also be end users when they run studies or source assay services.
Clinicians and laboratories buying DiviTum TKa to monitor cancer treatment response in practice.
Drug developers using TKa testing, study support, and biomarker services in clinical programs.
Smaller oncology developers using the platform for exploratory and validation studies.
Researchers buying assays or services for clinical studies and biomarker research.
Contract research organizations sourcing assay kits or centralized testing for sponsors.
Strategy
Biovica’s strategy is to expand adoption of DiviTum TKa in breast cancer, especially in the U.S., where it is commercialized through its own CLIA-certified laboratory. The company is also building Pharma Services as a second growth engine by supporting pharmaceutical partners with biomarker testing, study design, and companion diagnostic work. Longer term, it aims to broaden use into additional cancer types and geographies while deepening clinical evidence and payer acceptance.
The U.S. is the main market and the CLIA lab model supports direct commercialization.
Pharma collaborations diversify revenue and can create future CDx opportunities.
Published and real-world evidence supports physician adoption and payer acceptance.
Broader market access can increase the addressable market beyond the U.S. breast cancer base.
Geography
Biovica is headquartered in Uppsala, Sweden, with R&D and production based there and an office and laboratory in San Diego, California. The United States is its primary commercial market, while Europe is served through partners and laboratory/distributor arrangements. The business also has planned expansion into additional markets such as Japan, which broadens its regulatory and reimbursement exposure.
Risks
Biovica depends on adoption of a specialized biomarker test, so commercial execution, reimbursement, and clinical validation are central risks. The company also faces regulatory, financial, and foreign-exchange exposure because it operates across Sweden, the U.S., and other international markets. As a diagnostics and life science business, it is additionally exposed to competition from alternative biomarkers, slower-than-expected physician uptake, and the inherent uncertainty of pharma collaboration pipelines.
- Commercial adoption riskImpact: HighLikelihood: Medium
Revenue depends on clinicians and labs adopting a biomarker test in routine care.
Exposure: U.S. clinical market
- Reimbursement and payer riskImpact: HighLikelihood: Low
The U.S. model relies on reimbursement levels that support clinical use and scaling.
Exposure: U.S. market access
- Regulatory and compliance riskImpact: HighLikelihood: Low
The business operates under CLIA/LDT frameworks and may face changing diagnostics rules.
Exposure: United States and future international markets
- Currency riskImpact: MediumLikelihood: Medium
Operations and sales span Sweden, the U.S., and Europe, creating USD/EUR exposure.
Exposure - Pharma partnership concentrationImpact: MediumLikelihood: Low
A meaningful part of growth depends on onboarding and retaining large pharma customers.
Exposure: Pharma Services
Accounting
Judgemental itemsClinical tests, assay kits, and pharma services may be recognized at different points in time.
Impact: Affects quarterly revenue timing and comparability
Management must judge whether R&D projects are technically and commercially viable.
Impact: Affects intangible assets, amortization, and operating expense
DiviTum-related assets and patents depend on future adoption and cash generation.
Impact: Could create non-cash write-downs if assumptions weaken
Assay components and finished goods must be carried at lower of cost and net realizable value.
Impact: Can affect gross margin and write-downs
Employee and board incentive programs are used and must be expensed over vesting periods.
Impact: Affects operating expenses and equity dilution
Similar listed companies
Publicly listed companies with a comparable business focus.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Bio-Rad Laboratories, Inc
BIO · Laboratory Analytical Instruments
Bio-Rad Laboratories is a U.S.-based multinational that develops, manufactures, and sells tools used in life science research and clinical diagnostics.
BioLife Solutions, Inc
BLFS · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026